The LEO Foundation owns about 80% of LEO Pharma and exercises engaged, ambitious controlling ownership. Its primary objective is to ensure LEO Pharma’s long-term development and success as a global leader in medical dermatology.

Besides its ownership role, the Foundation is one of the world’s largest private funders of independent skin research. It provides philanthropic grants to support research that pioneers new discoveries and transforms our understanding of the skin and its diseases. Over the years, the LEO Foundation has awarded more than EUR 240 million.

In addition, the Foundation manages substantial financial assets. These assets are invested to ensure the Foundation’s continued capability to support LEO Pharma’s long-term continuation and strategic development and to provide a growing basis for philanthropic grants.